The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural
effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity
or by physician's preference. In this protocol, the treatment regimen will be assigned based
on the patients' tumor molecular profile. A tumor molecular profile analysis will allow the
physician to define a specific molecular portrait that shows the genetic basis of the tumor.
This analysis results in a detailed report that will determine which chemotherapy will be
assigned to the patient.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute